← All trials
NCT04346329
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 20, 2020
- Primary completion
- Jun 1, 2020
- Completion date
- Oct 1, 2020
- First posted
- Apr 15, 2020
- Last posted
- Apr 15, 2020
- Enrollment
- 86
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Universidad Nacional de ColombiaLead sponsor
- Universidad Nacional de ColombiaReponsible party - principal investigator
- Fundación Salud de los AndesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.